Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tumour mutational burden: clinical utility, challenges and emerging improvements
Jan Budczies, Daniel Kazdal, Michael Menzel, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 10, pp. 725-742
Closed Access | Times Cited: 20

Showing 20 citing articles:

Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors
Elena Catanzaro, Manuel Beltrán‐Visiedo, Lorenzo Galluzzi, et al.
Cellular and Molecular Immunology (2024)
Open Access | Times Cited: 11
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types
David R. Gandara, Neeraj Agarwal, Shilpa Gupta, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 2, pp. e010311-e010311
Open Access | Times Cited: 1
Tumour Mutational Burden and Immune Checkpoint Inhibitor Response in Non-small Cell Lung Cancer: A Continuous Modelling Approach
Michael J. Sorich, Arkady T. Manning‐Bennett, Lee X. Li, et al.
Targeted Oncology (2025)
Open Access
TMBocelot: an omnibus statistical control model optimizing the TMB thresholds with systematic measurement errors
Xin Lai, Shaoliang Wang, Xuanping Zhang, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Oncogenic competence: balancing mutations, cellular state, and microenvironment
Lisa Pavinato, Arianna Baggiolini
Trends in cancer (2025)
Closed Access
Peptide-Assisted CRISPR/Cas9 Delivery to Tumors
Oskar Gustafsson, Samir EL Andaloussi, Joel Z. Nordin
Methods in pharmacology and toxicology (2025), pp. 155-175
Closed Access
Defeating lethal cancer: Interrupting the ecologic and evolutionary basis of death from malignancy
Kenneth J. Pienta, Patrick L. Goodin, Sarah R. Amend
CA A Cancer Journal for Clinicians (2025)
Open Access
Programmed Cell Death Ligand as a Biomarker for Response to Immunotherapy: Contribution of Mass Spectrometry-Based Analysis
Marco Agostini, Pietro Traldi, Mahmoud Hamdan
Cancers (2025) Vol. 17, Iss. 6, pp. 1001-1001
Open Access
Deciphering the tumor immune microenvironment: Microscale measurements for precision detection and multidimensional analysis
Lu Wang, Fan Yin, Rongping Luo, et al.
View (2025)
Open Access
High Tumor Mutation Burden (TMB) and a Novel Somatic Mutation in the TREX1 Gene in a Patient with Aggressive and Refractory High-Grade B-Cell Lymphoma: A Case Report
M. S. Gusakova, Fedor Sharko, Eugenia Boulygina, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 2926-2926
Open Access
Comment on ‘Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types’
Jiawen Bu, Tong Zhu, Xudong Zhu
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 3, pp. e011943-e011943
Open Access
Unveiling purine metabolism dysregulation orchestrated immunosuppression in advanced pancreatic cancer and concentrating on the central role of NT5E
Junqian Zhang, Xiaobo Zhang, R. Wu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Assessing the prognostic and therapeutic value of cuproptosis-related genes in colon adenocarcinoma patients
Zhanhui Ye, Yixian Song, Mengqing Zhu, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 13
Open Access
A Comprehensive Review About the Use of Monoclonal Antibodies in Cancer Therapy
Angel A Justiz-Vaillant, Bijay Raj Pandit, Chandrashekhar Unakal, et al.
Antibodies (2025) Vol. 14, Iss. 2, pp. 35-35
Open Access
Impact of radiation therapy on the immunological tumor microenvironment
Emma Guilbaud, Flavie Naulin, Lydia Meziani, et al.
Cell chemical biology (2025)
Closed Access
Perturbation-Theory Machine Learning for Multi-Target Drug Discovery in Modern Anticancer Research
Valeria V. Kleandrova, M. Natália D. S. Cordeiro, Alejandro Speck‐Planche
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 5, pp. 301-301
Open Access
Nanotechnology-driven strategies in postoperative cancer treatment: innovations in drug delivery systems
Junjie Zhou, Yuanming Feng, Ming Zhao, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Liquid and Tissue Biopsies for Lung Cancer: Algorithms and Perspectives
Paul Hofman
Cancers (2024) Vol. 16, Iss. 19, pp. 3340-3340
Open Access | Times Cited: 1
THOR: a TMB heterogeneity-adaptive optimization model predicts immunotherapy response using clonal genomic features in group-structured data
Yixuan Wang, Yanfang Guan, Xin Lai, et al.
Briefings in Bioinformatics (2024) Vol. 26, Iss. 1
Open Access | Times Cited: 1
Predicting Tumor Mutational Burden from UHF-Dielectrophoresis Crossover Frequency
Héloïse Daverat, Nina Blasco, Sandrine Robert, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
An AI-Powered tissue-agnostic cellular morphometrics biomarker for risk assessment in patients with pan-gastrointestinal precancerous lesions and cancers
Pin Wang, Chengfei Jiang, Aiqin Mao, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Page 1

Scroll to top